Rakuten Securities Inc. Sells 391 Shares of AstraZeneca PLC (NASDAQ:AZN)

Rakuten Securities Inc. cut its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 30.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 890 shares of the company’s stock after selling 391 shares during the quarter. Rakuten Securities Inc.’s holdings in AstraZeneca were worth $69,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Harbour Investments Inc. raised its stake in AstraZeneca by 1.9% during the 3rd quarter. Harbour Investments Inc. now owns 8,805 shares of the company’s stock valued at $686,000 after purchasing an additional 160 shares during the period. Nations Financial Group Inc. IA ADV lifted its holdings in shares of AstraZeneca by 5.2% in the third quarter. Nations Financial Group Inc. IA ADV now owns 5,368 shares of the company’s stock worth $418,000 after buying an additional 267 shares in the last quarter. Venturi Wealth Management LLC boosted its position in shares of AstraZeneca by 13.0% during the third quarter. Venturi Wealth Management LLC now owns 25,796 shares of the company’s stock worth $2,010,000 after acquiring an additional 2,968 shares during the last quarter. Addison Advisors LLC grew its stake in AstraZeneca by 11.9% during the third quarter. Addison Advisors LLC now owns 1,743 shares of the company’s stock valued at $136,000 after acquiring an additional 186 shares in the last quarter. Finally, Catalytic Wealth RIA LLC increased its holdings in AstraZeneca by 7.0% in the 3rd quarter. Catalytic Wealth RIA LLC now owns 29,008 shares of the company’s stock valued at $2,260,000 after acquiring an additional 1,908 shares during the last quarter. 20.35% of the stock is owned by hedge funds and other institutional investors.

AstraZeneca Trading Up 0.6 %

Shares of AZN opened at $65.19 on Wednesday. The firm has a market capitalization of $202.13 billion, a price-to-earnings ratio of 31.49, a PEG ratio of 1.20 and a beta of 0.47. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.89 and a quick ratio of 0.69. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68. The company has a 50-day moving average of $76.61 and a 200 day moving average of $78.54.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. TD Cowen raised their target price on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.